What the news says
The news may affect the outlook for domestic biotechnology funds and stocks, particularly those with supply chains or partnerships linked to China.
07/09, 10:35 PM
CNBC's Jim Cramer states that biotech has become the market's hottest group, highlighting a strong move in the sector partly due to the change in FDA leadership.
CNBC's Jim Cramer states that biotech has become the market's hottest group, highlighting a strong move in the sector partly due to the change in FDA leadership.
Affected assets
finnhub-NVDA
07/09, 10:35 PM
Related updates
FirstSquawk · 07/17, 01:16 AM
Market reactionDassault Systèmes is in talks to acquire a drug trial software company for approximately $2 billion, according to the Financial Times.
FirstSquawk · 07/16, 07:47 AM
Market reactionA Senate bill aims to reduce US reliance on China in the drug industry.
FirstSquawk · 07/15, 10:51 PM
Market reactionNovo Nordisk received European Commission approval for a weight-loss pill version of Wegovy and a ready-to-use 7.2 mg pen.
jin10 · 07/15, 10:00 PM
Market reactionChinese domestic futures closed mixed overnight, with PTA down over 2%, synthetic rubber up over 1%, and plastic and soybean meal up nearly 1%.
wsj-markets · 07/12, 04:30 PM
Market reactionThe article questions whether AI can develop better drugs given Wall Street's short-term timeline, posing the question of whether investors should pay up for the technology.
marketwatch-top · 07/09, 04:53 PM
High impactA major drugmaker lost $27 billion in market value after a heart disease drug failed its Phase III trial.
bloomberg-industries · 07/09, 08:52 AM
Market reactionA Bloomberg Television interview with Paul Weiss M&A co-head notes that biotech dealmaking in 2026 has hit a torrid pace, with more deals over $1 billion already this year than in all of 2025.